The points raised by Sharuia et al, in their letter "Does Carbainazepine Alter the Electro-Convulsive Threshold" (Joumal,27 173-174:1985) are topical and interesting. 1 lowever, the inference ... "Carbamazepine may be interfering with seizure threshold and...therapeutic induction of seizures" seems clouded by the following :-The patient was getting lithium 1800 mg., Carbamazepine (CBZ) 800 mg. and I'henob.irbitone (PB) 60 mg./day. It is difficult, especially in an epileptic subject, to incriminate CBZ alone out of combination of these three drugs which interact with each other in a complex manner and influence seizure activity. Absctuc or scrum levels of PB and CBZ further limits the experimental design and the scope of extrapolation of the data. In addition, animal experiments indicate that CBZ suppresses kindling process by repetitive sub-threshold electrical stimulation of the limbic structures and propagation of kindled seizure discharge to other brain areas (Wada 1977) . On the whole, the evidence to date suggests that the site of action of CBZ is predominantly on the limbic structures rather than the midbrain reticular formation or thalamus.
In the light of these data, and in keeping with the pioneering works of Kobayashi and co-workers (1967) as quoted by Okuma (1983), we feel that... "Carbamazepine produces no significant change in seizure threshold". This conviction is further strengthened by our recent observation on two patients; while on CBZ alone (600-900 mg/day), both could be given ECT with usual voltage and duration as in those patients not on CBZ. The patients reported by the authors might have needed more than average duration and stimulus due to presence of I'B. It may well be that the A-B-A-B design the authors employed itself had been responsible for lesser requirement ot stimulus and its duration. The altered schedule of CBZ 400 mg. a.m. and afternoon on the day previous to ECT had probably led to a state of relative CBZ withdrawal on the next morning when ECT was given. This withdrawal accentuated further by PB, could have lowered the seizure threshold by producing an altered biological state in a predisposed subject; this was corrected in the next phase when the original t.i.d. schedule was resumed.
It is not quite understandable how... "combined GABA-ergic effect of CBZ and ECT" could be held for the observations reported by the authors. 
Reply
Sir,
The points raised by Dr. Goswami et al are only partially correct. We would like to clarify that the patient in question was receiving carbamazepine only for control of seizures, and not in combination with phenobarbitone. The other two patients too were not on phenobarbitonc. Lithium does not alter after discharge threshold and seizure severity of hippocampal kindled seizures in rats after acute administration, and is unlikely to do so after prolonged used (Clifford ct al 1985) . Kobayashi's statement has already been referred to in our letter, along with a contrary observation. It onlv serves to highlight the divergence of opinion in the field.
They go on to suggest regarding the state ot "relative CBZ withdrawal". Induced seizures have not been studied at various blood levels, which in any case fluctuate, it would be worthwhile to remember that peak CBZ levels occur more than 6 hours after (range 2-12 hrs), whereas the half life is around 20 hrs in those receiving it chronically (Kutt 1978) . It is not very clear yet whether experimental seizures depend upon peak or steady state level, and which one ot these the 'relative withdrawal' refers to. In any case, it is an interesting observation as it illustrates the disparity between induced and spontaneous seizures. It is not clear how l'B, even it it had been given, could have accentuated the withdrawal.
ECT induces a variety ot effects associated with ami kindling and anti-con vulsant properties. It increases benzodiazepine binding, and potentiates GABA-ergic and Catecholamincrgic mechanism in addition to various effects on peptides and hormones (Post et al 1984) . These authors propose these observations as an explanation for the paradox of an anticonvulsant drug and a convulsive treatment being simultaneously efficient in the treatment of affective disorder. The mechanism of the anti-epileptic action of GBZ is not well understood. GABA-ergic, adenosine receptor and benzodia7.epine receptor effects have all been implicated, as arso in the affective disorders (Morselli & Lloyd 1985 , Post et al 1984 . We have specifically stated that CBZ may interfere with the therapeutic induction of seizures and not the treatment response per se. We agree that the site of action of CBZ is predominantly on the limbic structures.
